Cannabis Global Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Cannabis Global's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Aug 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Cannabis Global makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 22 | 1 | -14 | 2 | 0 |
| 31 May 22 | 3 | -3 | 2 | 0 |
| 28 Feb 22 | 3 | -5 | 3 | 0 |
| 30 Nov 21 | 2 | -7 | 2 | 0 |
| 31 Aug 21 | 2 | -8 | 2 | 0 |
| 31 May 21 | 1 | -6 | 3 | 0 |
| 28 Feb 21 | 0 | -6 | 4 | 0 |
| 30 Nov 20 | 0 | -5 | 4 | 0 |
| 31 Aug 20 | 0 | -5 | 4 | 0 |
| 31 May 20 | 0 | -4 | 3 | 0 |
| 29 Feb 20 | 0 | -2 | 1 | 0 |
| 30 Nov 19 | 0 | -1 | 1 | 0 |
| 31 Aug 19 | 0 | 0 | 1 | 0 |
| 31 May 19 | 0 | 0 | 0 | 0 |
| 28 Feb 19 | 0 | 0 | 0 | 0 |
| 30 Nov 18 | 0 | 0 | 0 | 0 |
| 31 Aug 18 | 0 | 0 | 0 | 0 |
| 31 May 18 | 0 | 0 | 0 | 0 |
| 28 Feb 18 | 0 | 0 | 0 | 0 |
| 30 Nov 17 | 0 | 0 | 0 | 0 |
| 31 Aug 17 | 0 | 0 | 0 | 0 |
| 31 May 17 | 0 | 0 | 0 | 0 |
| 28 Feb 17 | 0 | 0 | 0 | 0 |
| 30 Nov 16 | 0 | 0 | 0 | 0 |
| 31 Aug 16 | 0 | 0 | 0 | 0 |
| 31 May 16 | 0 | 0 | 0 | 0 |
| 29 Feb 16 | 0 | 0 | 0 | 0 |
| 30 Nov 15 | 0 | 0 | 0 | 0 |
| 31 Aug 15 | 0 | 0 | 0 | 0 |
| 31 May 15 | 0 | 0 | 0 | 0 |
| 28 Feb 15 | 0 | 0 | 0 | 0 |
| 30 Nov 14 | 0 | 0 | 0 | 0 |
| 31 Aug 14 | 0 | 0 | 0 | 0 |
| 31 May 14 | 0 | 0 | 0 | 0 |
| 28 Feb 14 | 0 | 0 | 0 | 0 |
Quality Earnings: Insufficient data to determine if CBGL has high quality earnings.
Growing Profit Margin: Insufficient data to determine if CBGL's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CBGL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare CBGL's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if CBGL's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: CBGL has a negative Return on Equity (0%), as it is currently unprofitable.